




RealRate

PHARMACEUTICAL 2020

Altimmune Inc.
Rank 142 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Altimune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Altimune Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Altimune Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is -106%, being 197% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	39,395
Cost of Goods Sold	0
Intangible Assets	12,732
Liabilities, Current	3,923
Liabilities, Non-Current	0
Other Assets	827
Other Compr. Net Income	20
Other Expenses	942
Other Liabilities	4,615
Other Net Income	886
Property and Equipment	1,104
Research and Development	17,766
Revenues	5,801
Selling, General and Administrative Expense	8,501

Output Variable	Value in 1000 USD
Assets	54,058
Liabilities	8,538
Expenses	27,208
Stockholders Equity	45,520
Net Income	-20,520
Comprehensive Net Income	-20,510
Economic Capital Ratio	-106%